Second primary tumor after immune checkpoint inhibitor therapy: A case report

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) are standard cancer treatments.
• The impact of ICIs on the risk of developing second primary tumors remains uncertain.
• Conflicting evidence exists regarding whether ICIs decrease or increase second primary cancer incidence.

Observation:

• A patient with advanced non-small cell lung cancer (NSCLC) received combination therapy with ICIs and antiangiogenic drugs.
• The patient experienced a favorable treatment response for the primary NSCLC.
• Despite effective primary treatment, the patient developed a second primary tumor.

Findings:

• Effective treatment of a primary cancer with ICIs does not preclude the development of a second primary tumor.
• The occurrence of a second primary tumor can be independent of the primary tumor's response to ICI therapy.

Implications:

• Clinicians must consider the possibility of second primary tumors in patients treated with ICIs.
• New or worsening symptoms in patients on ICIs should prompt evaluation for a second primary cancer, not just disease progression.
• This case underscores the complex relationship between immunotherapy and secondary oncogenesis.